BPC-157 (Body Protection Compound-157)

BPC-157 is a synthetic pentadecapeptide corresponding to a 15-amino-acid sequence originally identified as a fragment of a protein isolated from human gastric juice. It is a linear, non-glycosylated peptide with no disulfide bonds, which is the structural reason it behaves as a comparatively robust molecule in aqueous solution.

Because it is short, linear, and free of cysteine residues, BPC-157 is straightforward to synthesize by solid-phase methodology and straightforward to characterise analytically — a single dominant peak on reverse-phase HPLC, and a clean multiply-charged envelope on electrospray ionisation mass spectrometry. This combination is why it is widely used as a reference material for method development and chromatographic calibration, independent of any biological application.

The compound is supplied as a lyophilized powder so that it can be stored and shipped at ambient temperature without measurable degradation of the peptide backbone, and reconstituted only at the point of use.

The following summarises mechanisms reported in preclinical and in-vitro literature. It is provided for scientific orientation only and does not describe any approved or established clinical application.

Early growth response protein 1 (EGR-1)

Several in-vitro studies report rapid upregulation of EGR-1 transcription following exposure of fibroblast and endothelial cell cultures to BPC-157, and have proposed this as one of the earliest transcriptional events in the observed response.

Focal adhesion kinase (FAK) and paxillin

Cell migration assays describe activation of the FAK–paxillin axis and reorganisation of focal adhesion complexes, consistent with increased directional motility in cultured cells.

Angiogenic signalling in vitro

Endothelial tube-formation assays report increased network formation and VEGF receptor 2–associated signalling. These are cell-culture observations; no vessel formation in living organisms is claimed here.

Gastric acid stability

BPC-157 has been reported to resist degradation in acidic media that rapidly hydrolyse most peptides, which is the property most often cited in the literature describing its discovery.

Note on evidence status

The published record for BPC-157 is dominated by in-vitro work and rodent models. No Phase III human trial data exist, and the compound is not approved as a medicine in any jurisdiction.

Every lot is released against three independent checks:

1. Purity — RP-HPLC. C18 column, gradient acetonitrile/water with 0.1% TFA, UV detection at 220 nm. Purity is reported as main-peak area percentage. Acceptance criterion ≥ 99.0%; typical observed values fall between 99.0% and 99.6%.
2. Identity — ESI-MS. The observed multiply-charged ion series is deconvoluted and compared against the theoretical monoisotopic mass of 1419.53 Da. A mass error within ±0.5 Da is required for release.
3. Appearance and solubility. Visual inspection of the lyophilized cake; solubility confirmed in water at working concentrations used for standard preparation.

The chromatogram and mass spectrum for the specific lot you receive are bound into that lot's Certificate of Analysis. Enter your lot number in the COA registry to pull the exact document.

This protocol is written for preparing calibration standards for instrumental analysis. It is not a preparation guide for any biological or human application.

1. Equilibrate. Bring the sealed vial to room temperature before opening, to prevent condensation onto the powder.
2. Weigh, if required. For gravimetric standards, tare a calibrated analytical balance and transfer the powder with a static-free spatula.
3. Dissolve. Add sterile deionised water or an appropriate aqueous buffer, directing the stream down the vial wall rather than onto the cake. Target concentrations for HPLC calibration typically fall in the 0.1–1.0 mg/mL range, adjusted to your method.
4. Mix gently. Swirl; do not vortex. Vigorous agitation introduces shear and air bubbles that degrade injection reproducibility.
5. Filter if required by your method. 0.22 µm PVDF or PTFE, depending on column compatibility.
6. Use freshly prepared. Aqueous peptide solutions are subject to hydrolysis and are not intended for long-term storage. Prepare what you need for the run.

Do not subject solutions to repeated freeze–thaw cycles. If you must hold a solution, aliquot once and freeze at −20 °C or below, protected from light.

This product is a chemical reference standard intended exclusively for in-vitro laboratory research and analytical method development. It is not a pharmaceutical, drug, food, food additive, cosmetic, or veterinary product. It has not been evaluated or approved by the FDA, EMA, MHRA, TGA, or any other regulatory authority for any human or animal application, and it must not be administered to humans or animals.

By purchasing, the buyer represents that they are a qualified researcher or institution with the facilities and training to handle biochemical reference materials safely, and that the material will be used only for lawful in-vitro investigation.